At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 81 enrolled
Drug / intervention
25 mg Omecamtiv Mecarbil +3 moredrug
Likely dose
25 mg Omecamtiv Mecarbilfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
In Brief
A Phase 2 clinical trial evaluating 25 mg Omecamtiv Mecarbil, Placebo, and 2 other interventions for Heart Failure With Reduced Ejection Fraction. Completed, enrolled 81 participants across 32 sites.
Detailed Summary
* To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction * To evaluate the safety and tolerability of oral omecamtiv mecarbil
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionApr 2017
Study CompletionMay 2017
TodayJul 2026
First PostedMar 1, 2016
Enrollment StartApr 14, 2016
Primary CompletionApr 6, 2017
Study CompletionMay 8, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.3 years ago
Interventions
25 mg Omecamtiv Mecarbildrug
oral tablet
Placebodrug
oral tablet
37.5 mg Omecamtiv Mecarbildrug
oral tablet
50 mg Omecamtiv Mecarbildrug
oral tablet